Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
12
LEGN Quote, Financials, Valuation and Earnings
Last price:
$21.50
Seasonality move
:
-8.43%
Day range:
$21.35 - $21.91
52-week range:
$21.19 - $45.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.35x
P/B ratio:
3.93x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
-38.07%
Market cap:
$4B
Revenue:
$627.6M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$328.9M | -$0.07 | 69.75% | -33.34% | $72.24 |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -66.99% | $20.64 |
|
CABA
Cabaletta Bio, Inc.
|
-- | -$0.44 | -- | -27.29% | $14.13 |
|
CRMD
CorMedix, Inc.
|
$127.4M | $0.72 | 308.6% | 219.78% | $19.00 |
|
EXEL
Exelixis, Inc.
|
$624.6M | $0.70 | 7.5% | 59.24% | $45.28 |
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.30 | -- | -27.21% | $53.56 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$21.51 | $72.24 | $4B | -- | $0.00 | 0% | 4.35x |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.31 | $20.64 | $287.8M | 4.56x | $0.00 | 0% | 717.87x |
|
CABA
Cabaletta Bio, Inc.
|
$2.21 | $14.13 | $212.7M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$12.16 | $19.00 | $958.1M | 5.92x | $0.00 | 0% | 4.09x |
|
EXEL
Exelixis, Inc.
|
$43.58 | $45.28 | $11.7B | 18.35x | $0.00 | 0% | 5.45x |
|
TERN
Terns Pharmaceuticals, Inc.
|
$40.11 | $53.56 | $3.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
28.86% | 0.847 | 6.82% | 2.29x |
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.025 | 8.71% | 9.35x |
|
CABA
Cabaletta Bio, Inc.
|
15.6% | 5.600 | 11.44% | 3.50x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.175 | 1.59% | 3.47x |
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | -0.513 | 0.16% | 19.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$151.1M | -$43.5M | -16.97% | -23.01% | -15.96% | $15.2M |
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
CABA
Cabaletta Bio, Inc.
|
-$345K | -$46.6M | -90.44% | -103.46% | -- | -$34.6M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
Legend Biotech Corp. vs. Competitors
-
Which has Higher Returns LEGN or ABEO?
Abeona Therapeutics, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Abeona Therapeutics, Inc.'s return on equity of 88.36%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M -
What do Analysts Say About LEGN or ABEO?
Legend Biotech Corp. has a consensus price target of $72.24, signalling upside risk potential of 235.84%. On the other hand Abeona Therapeutics, Inc. has an analysts' consensus of $20.64 which suggests that it could grow by 288.75%. Given that Abeona Therapeutics, Inc. has higher upside potential than Legend Biotech Corp., analysts believe Abeona Therapeutics, Inc. is more attractive than Legend Biotech Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 ABEOAbeona Therapeutics, Inc.6 0 0 -
Is LEGN or ABEO More Risky?
Legend Biotech Corp. has a beta of 0.124, which suggesting that the stock is 87.622% less volatile than S&P 500. In comparison Abeona Therapeutics, Inc. has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.436%.
-
Which is a Better Dividend Stock LEGN or ABEO?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abeona Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Abeona Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or ABEO?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Abeona Therapeutics, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is lower than Abeona Therapeutics, Inc.'s net income of -$5.2M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Abeona Therapeutics, Inc.'s PE ratio is 4.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.35x versus 717.87x for Abeona Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.35x -- $272.7M -$39.7M ABEOAbeona Therapeutics, Inc.717.87x 4.56x -- -$5.2M
-
Which has Higher Returns LEGN or CABA?
Cabaletta Bio, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Cabaletta Bio, Inc.'s return on equity of -103.46%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B CABACabaletta Bio, Inc.-- -$0.44 $165.2M -
What do Analysts Say About LEGN or CABA?
Legend Biotech Corp. has a consensus price target of $72.24, signalling upside risk potential of 235.84%. On the other hand Cabaletta Bio, Inc. has an analysts' consensus of $14.13 which suggests that it could grow by 539.14%. Given that Cabaletta Bio, Inc. has higher upside potential than Legend Biotech Corp., analysts believe Cabaletta Bio, Inc. is more attractive than Legend Biotech Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 CABACabaletta Bio, Inc.7 2 0 -
Is LEGN or CABA More Risky?
Legend Biotech Corp. has a beta of 0.124, which suggesting that the stock is 87.622% less volatile than S&P 500. In comparison Cabaletta Bio, Inc. has a beta of 3.249, suggesting its more volatile than the S&P 500 by 224.938%.
-
Which is a Better Dividend Stock LEGN or CABA?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cabaletta Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Cabaletta Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or CABA?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Cabaletta Bio, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is higher than Cabaletta Bio, Inc.'s net income of -$44.9M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Cabaletta Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.35x versus -- for Cabaletta Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.35x -- $272.7M -$39.7M CABACabaletta Bio, Inc.-- -- -- -$44.9M
-
Which has Higher Returns LEGN or CRMD?
CorMedix, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of 49.9%. Legend Biotech Corp.'s return on equity of -23.01% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About LEGN or CRMD?
Legend Biotech Corp. has a consensus price target of $72.24, signalling upside risk potential of 235.84%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 56.25%. Given that Legend Biotech Corp. has higher upside potential than CorMedix, Inc., analysts believe Legend Biotech Corp. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 CRMDCorMedix, Inc.4 0 0 -
Is LEGN or CRMD More Risky?
Legend Biotech Corp. has a beta of 0.124, which suggesting that the stock is 87.622% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock LEGN or CRMD?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or CRMD?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Legend Biotech Corp.'s net income of -$39.7M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.35x versus 4.09x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.35x -- $272.7M -$39.7M CRMDCorMedix, Inc.4.09x 5.92x $104.3M $108.6M
-
Which has Higher Returns LEGN or EXEL?
Exelixis, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of 32.38%. Legend Biotech Corp.'s return on equity of -23.01% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About LEGN or EXEL?
Legend Biotech Corp. has a consensus price target of $72.24, signalling upside risk potential of 235.84%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could grow by 3.9%. Given that Legend Biotech Corp. has higher upside potential than Exelixis, Inc., analysts believe Legend Biotech Corp. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 EXELExelixis, Inc.9 9 0 -
Is LEGN or EXEL More Risky?
Legend Biotech Corp. has a beta of 0.124, which suggesting that the stock is 87.622% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.171%.
-
Which is a Better Dividend Stock LEGN or EXEL?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or EXEL?
Legend Biotech Corp. quarterly revenues are $272.7M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Legend Biotech Corp.'s net income of -$39.7M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.35x versus 5.45x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.35x -- $272.7M -$39.7M EXELExelixis, Inc.5.45x 18.35x $597.8M $193.6M
-
Which has Higher Returns LEGN or TERN?
Terns Pharmaceuticals, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M -
What do Analysts Say About LEGN or TERN?
Legend Biotech Corp. has a consensus price target of $72.24, signalling upside risk potential of 235.84%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $53.56 which suggests that it could grow by 33.52%. Given that Legend Biotech Corp. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Legend Biotech Corp. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 TERNTerns Pharmaceuticals, Inc.8 0 0 -
Is LEGN or TERN More Risky?
Legend Biotech Corp. has a beta of 0.124, which suggesting that the stock is 87.622% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LEGN or TERN?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or TERN?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.35x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.35x -- $272.7M -$39.7M TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 4
Claritev Corp. [CTEV] is down 20.7% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
Sell
47
ASTS alert for Jan 4
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
